Britannia Life Sciences arranges $10-million financing

Executive Summary

• Britannia Life Sciences Inc. has launched a non-brokered private placement offering of unsecured debentures to raise gross proceeds of up to $10 million.
• The capital will be used to provide investors with exposure to a fixed-return portfolio of asset-backed loans, leveraging the company's expansion into the specialty finance and private debt sectors.
• The debentures carry an 18% annual interest rate, have a 10-year term, and are scheduled to close by September 15, 2025.

Key Details

• Offering Size: Up to $10 million in gross proceeds.
• Instrument Type: Unsecured debentures.
• Interest Rate: 18% per annum, paid monthly.
• Accrual Terms: 60-day delayed accrual period before interest payments begin.
• Term: 10 years from the date of issuance.
• Listing: Subject to listing on the Canadian Securities Exchange (CSE), pending satisfaction of CSE requirements.
• Redemption: Redeemable by the company after two years at 101% of the then-prevailing market price.
• Minimum Subscription: $50,000.
• Use of Proceeds: To provide debentureholders with exposure to a portfolio of asset-backed loans with strong underlying collateral and monthly interest income.
• Hold Period: Four-month hold period under applicable Canadian securities laws.
• Closing Date: Expected on or before September 15, 2025.
• Regulatory Status: Subject to customary closing conditions and regulatory approvals, including CSE approval.
• Strategic Context: Part of Britannia's expansion into specialty finance, originating and administering investments in private debt and non-resource royalty markets.

Notable Quotes

• "This offering allows Britannia to provide accredited and institutional investors with direct exposure to an arm's-length portfolio of asset-backed, income-generating assets," said Peter Shippen, chief executive officer of Britannia Life Sciences. "By focusing on unique opportunities in underserved markets, we're able to deliver attractive yields while still being supported by high-quality collateral."